Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences

Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.
 

 

 

University of Pittsburgh Schools of the Health Sciences

​University Of Pittsburgh Cancer Institute Study Confirms Efficacy Of Taxol Regimen In The Treatment Of Advanced Lung Cancer

Los Angeles/Pittsburgh, May 19, 1998 — Results from a large, randomized, phase III study confirmed the efficacy of paclitaxel plus carboplatin in the treatment of non-small cell lung cancer (NSCLC). These data were presented here at the 34th annual meeting of the American Society of Clinical Oncology.

This study was designed to compare paclitaxel/carboplatin to cisplatin/etoposide. The trial enrolled 369 patients with advanced or metastatic NSCLC between May 1995 and July 1996. One hundred seventy-nine patients received cisplatin/etoposide and 190 received paclitaxel/carboplatin. After initial therapy, patients could receive additional chemotherapy.

"Survival in the control arm (cisplatin/etoposide) was unexpectedly higher, and this could be attributable to multiple factors, including second-line chemotherapy with a taxane-based regimen," said Chandra Belani, M.D., associate professor of medicine at the University of Pittsburgh School of Medicine and co-director of the Lung Cancer Program at the University of Pittsburgh Cancer Institute (UPCI).

"Patients in the paclitaxel arm of the study experienced a greater response rate compared to cisplatin/etoposide, 23 percent versus 14 percent respectively," explained Dr. Belani. "Patients who received paclitaxel/carboplatin experienced improvement in quality of life from baseline to third course of chemotherapy."

"In 1998 we are not only talking about first-line therapy NSCLC, but we now need to pursue second-line chemotherapy," concluded Dr. Belani.

The ongoing phase III studies with the paclitaxel/carboplatin regimen being performed by the SWOG, ECOG, CALGB will further substantiate the results of this regimen with NSCLC.

Lung cancer is one the most common cancers in the United States, representing about 15 percent of all cancer cases, or 178,000 new cases in 1997. Lung cancer accounts for over one-fourth (28 percent) of cancer deaths in the United States; it is the number one killer by cancer and in fact, kills more people than colon, prostate and breast cancer combined. At this time, over half of the lung cancer cases in the United States are in men, but the number of women diagnosed each year is increasing and will surpass that in men.

As one of 31 NCI-designated comprehensive cancer centers, the UPCI is recognized for its interdisciplinary approach to cancer prevention, detection, diagnosis, treatment, education and community outreach and for its commitment to translational research that rapidly brings new cancer therapies from the laboratory bench to the patient’s bedside.

For additional information about this study, please contact the UPCI’s Cancer Information and Referral Service toll-free at 800-237-4PCI(724) or visit the University of Pittsburgh Cancer Institute website.

 

 
 

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com